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Injuries are responsible for more deaths 
per year than HIV/AIDS, tuber culosis and 
malaria combined.[1] Furthermore, each year 
~4 million people die as a result of traumatic 
injuries and violence worldwide. In South 
Africa, trauma is a major concern, with 
violence and road traffic accidents being 
the fifth and seventh leading causes of death 
respectively.[2] Antifibrinolytic agents have 
been used in trauma and major surgery to 
prevent fibrinolysis and reduce blood loss. 
We summarise the evidence from an 
updated Cochrane review[3] investigating the 
effect of antifibrinolytic drugs in patients 
with acute traumatic injury. 
Methods
The review authors conducted comprehen­
sive literature searches in January 2015. All 
randomised controlled trials comparing anti­
fibrinolytic agents (aprotinin, tranex amic acid 
(TXA), epsilon aminocaproic acid and amino­
methylbenzoic acid) administered after acute 
traumatic injury were included. No restric­
tions were made with regard to language, 
date or publication status. Standard Cochrane 
methods for independent data screening and 
eligibility assessment, data extraction and risk­
of­bias evaluation were followed.
Results
Three randomised controlled trials were inclu­
ded, of which two (n=20  451) assessed the 
effect of TXA. The Clinical Randomisation of 
an Antifibrinolytic in Significant Haemorrhage 
(CRASH)­2 trial (n=20 211),[4] the larger of 
the two, was conducted in 40 countries and 
included patients with a variety of trauma 
types; the other specifically investigated 
patients with traumatic brain injury (TBI) 
(n=240). The third trial assessed aprotinin 
in participants with major bony trauma and 
shock. All three trials[3] provided data for 
meta­analysis. 
Antifibrinolytics reduced the risk of 
death by 10% (relative risk (RR) 0.90, 95% 
confi dence interval (CI) 0.85 ­ 0.96; three 
trials, high­quality evidence) compared 
with placebo. It should be noted that this 
estimate was largely based on the results of 
CRASH­2, a metho dologically rigorously 
conducted trial. 
The authors found that antifibrinolytics 
do not have adverse effects on the risk of 
vascular occlusive events, such as deep vein 
thrombosis, stroke or pulmonary embolism 
(moderate­quality evidence). TXA reduced 
the risk of myocardial infarction by 39% 
(RR 0.61, 95% CI 0.40 ­ 0.92; two trials, 
moderate­quality evidence). Further results 
are shown in Table 1. 
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In South Africa, trauma is a major concern, with violence and road traffic accidents being the fifth and seventh leading causes of death, 
respectively. Antifibrinolytic agents have been used in trauma and major surgery to prevent fibrinolysis and reduce blood loss. We highlight 
an updated Cochrane review investigating the effect of antifibrinolytic drugs in patients with acute traumatic injury. The review authors 
conducted comprehensive literature searches in January 2015 with regard to all randomised controlled trials comparing antifibrinolytic 
agents after acute traumatic injury. Three randomised controlled trials, of which two (n=20 451) assessed the effect of tranexamic acid 
(TXA), were included. The authors concluded that TXA safely reduces mortality in trauma with bleeding without increasing the risk of 
adverse events. TXA should be administered as early as possible, and within 3 hours of injury. There is still uncertainty with regard to the 
effect of TXA on patients with traumatic brain injury; however, ongoing randomised controlled trials should shed more light on this.
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Table 1. Summary of findings*† 
Outcomes
Relative effect  
(95% CI)
Study participants, n 
(RCT, n)
Quality of the 
evidence, grade‡
Mortality RR 0.90
(0.85 ­ 0.96)
20 437 (3) ⊕⊕⊕⊕
High
Surgical intervention RR 1.00
(0.97 ­ 1.03)
20 437 (3) ⊕⊕⊕⊕
High
Blood transfusion RR 0.98
(0.96 ­ 1.01)
20 367 (2) ⊕⊕⊕⊕
High
Myocardial infarction RR 0.61
(0.40 ­ 0.92)
20 367 (2) ⊕⊕⊕⊝
Moderate§
Deep vein thrombosis RR 0.95
(0.62 ­ 1.47)
20 367 (2) ⊕⊕⊕⊝
Moderate§
Stroke RR 0.86
(0.61 ­ 1.23)
20 367 (2) ⊕⊕⊕⊝
Moderate§
Pulmonary embolism RR 1.01
(0.73 ­ 1.41)
20 367 (2) ⊕⊕⊕⊝
Moderate§
CI = confidence interval; RR = risk ratio; RCT = randomised controlled trial. 
*Adapted from Ker K, et al.,[3 ] with permission.
† Population: treating bleeding trauma patients; settings: hospital settings in 40 countries;[4] intervention/comparison:    
antifibrinolytic drugs v. placebo.
‡ Grade = working group grades of evidence; high quality = further research is very unlikely to change our confidence in the 
estimate of effect; moderate quality = further research is likely to have an important impact on our confidence in the estimate of 
effect and may change the estimate; low quality = further research is very likely to have an important impact on our confidence in 
the estimate of effect and is likely to change the estimate; very low quality = we are very uncertain about the estimate.
§Downgraded one level for imprecision: estimate based on few events and wide CIs. 
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The TBI subgroup of patients who received TXA may be less likely to 
die (all­cause mortality) compared with patients who received placebo 
(RR 0.63, 95% CI 0.40 ­ 0.99; two trials, n=510, low­quality evidence); 
the low number of events and relative imprecision resulted in the 
downgrading of overall confidence in the results. Stronger evidence 
exists for the reduced risk of volume of intracranial bleeding with 
TXA in TBI patients compared with placebo (RR 0.75, 95% CI 0.58 ­ 
0.98; subgroup n=478, high­quality evidence). 
Conclusion
The review authors concluded that TXA safely reduces mortality in 
trauma with bleeding, without increasing the risk of adverse events. TXA 
should be given as early as possible and within 3 hours of injury. There 
is still uncertainty with regard to the effect of TXA on patients with TBI; 
however, ongoing randomised controlled trials should shed more light 
on this. Evidence from this review has been incorporated into trauma 
clinical practice guidelines[5] by the National Institute for Health and 
Care Excellence (NICE) in the UK, which has made recommendations 
for TXA use in both in­hospital and prehospital settings. 
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